Monopar Therapeutics (MNPR)
(Delayed Data from NSDQ)
$0.72 USD
+0.02 (2.29%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $0.73 +0.01 (1.37%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MNPR 0.72 +0.02(2.29%)
Will MNPR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MNPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MNPR
Bears are Losing Control Over Monopar Therapeutics (MNPR), Here's Why It's a 'Buy' Now
Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
MNPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy
Monopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Other News for MNPR
Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
Monopar announces acceptance of MNPR-101-RIT abstract for EANM 2024
Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
Monopar Therapeutics Enhances Alliance with NorthStar Medical